期刊文献+

慢性心力衰竭患者血浆肾上腺髓质素前体N端20肽与缩血管活性物质关系的探讨 被引量:2

Relationship of proadrenomedullin N terminal 20 peptide and the other vasoconstrictive substance in patients with chronic heart failure
原文传递
导出
摘要 目的 观察心力衰竭患者血浆肾上腺髓质素前体N端 2 0肽 (proadrenomedullinNterminal 2 0peptide ,PAMP)水平的变化并探讨其病理生理作用。 方法  (1)对照组 :健康体检人员 18例 ,男性 9例 ,女性 9例 ,年龄 3 0~ 60岁 ,平均 50 2 5岁。 (2 )慢性心力衰竭组 :符合NYHA心力衰竭标准 2 2例 ,男 15例 ,女 7例 ,年龄 3 9~ 70岁 (平均 65 5岁 ) ,心功能Ⅱ~Ⅲ级。用放免方法测定血浆PAMP、血管紧张素Ⅱ (AngⅡ )、内皮素 (ET)含量 ,高压液相测定血浆去甲肾上腺素 (NE)和肾上腺素(E)水平。采用二维超声心动图测定左室舒张期末径 ,Simpson法测定左室射血分数。结果 对照组PAMP为 (18 42± 2 3 3 )ng/L ,慢性心力衰竭组PAMP为 (2 9 3 7± 3 14 )ng/L(P <0 0 5) ;病情严重者 ,PAMP升高明显。慢性心力衰竭组患者血浆PAMP水平与AngⅡ、ET、NE、E呈显著正相关(P <0 0 5) ,与左室射血分数呈显著负相关。结论 慢性心力衰竭组血浆PAMP水平明显高于对照组 ,病情严重者 ,PAMP升高明显 ;AngⅡ等缩血管物质可能刺激PAMP的合成或分泌。升高的PAMP参与了心力衰竭的病理过程 。 Objective The novel hypotensive peptide, proadrenomedullin N-terminal 20 peptide (PAMP) is processed from the adrenomedullin precursor The PAMP has many function on cardiovascular physiology In this study the plasma levels in the patients with heart failure(HF) were investigated and the pathophysiological effect was discussed Methods Venous blood samples at rest were obtained from patients with HF in New York Heart Association functional classes II and III and from normal subjects The plasma levels of PAMP, angiotensin II(Ang II) , endothilin(ET) were measured with radioimmunoassay and norepinephrine(NE)?epinephrine(E) were measured with HPLC Left ventricular ejection fraction(LVEF) and Left ventricular end diastolic diameter (LVEDD) were measured by echocardiography in all the patients Results The mean plasma level of PAMP was 18 42±2 33ng/L in control group, and 29 37±3 14 ng/L in HF group ,which was 1 53 times higher in HF than that in control group (P<0 05) There was a positive correlation between plasma levels of PAMP and Ang II,ET,NE,E(P<0 05) significantly LVEF inversely correlated with plasma levels of PAMP (P<0 05) Conclusion The plasma levels of PAMP were higher in HF patients than that in control group The vasoconstrictive substance such as Ang II probably be related to its synthesis or secretion, which may involved in the pathophysiological process of HF The elevation of plasma level of PAMP may play the protective role for the patients with HF
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2003年第8期600-602,共3页 Chinese Journal of Cardiology
关键词 心力衰竭 血浆肾上腺髓质素前体 缩血管活性物质 ADM 氨基酸 Heart failure,congestive Renin-angiotensin system Left ventricular ejection fraction
  • 相关文献

参考文献9

  • 1苏加林,汪丽蕙,张继峰,夏冰,刘秀华,唐朝枢.肾上腺髓质素前体不同肽段的心血管效应[J].基础医学与临床,1999,19(1):33-37. 被引量:15
  • 2Tsuruda T, Kato J, Kitamura K, et al. Secretion of proadrenomedullin N-terminal 20 peptide from cultured neonatal rat cardiac cells. Life Sci, 2001,69: 239-245.
  • 3Kitamura K, Kangwa K, Kawamoto M, et al. Adrenomedullin : a novel hypotension peptise isolate from human pheochromocytoma. Biochem Biophys Res Commun, 1993,192:552-600.
  • 4Kitamura K, Sakata J, Kangwa K, et al. Cloning and characterization of cDNA encoding a precusor for human adrenomedullin. Biochem Biophys Res Commun, 1993, 194:720-725.
  • 5Shimosawa T, Fujita T. Hypotensive effect of a newly identified proadrenomedullin N-terminal 20 peptide (PAMP). Hypertension, 1996, 28:325-329.
  • 6Champion HC, Irickson CC, Simoneaux ML, et al. proadrenomedullin NH2-terminat 20 peptide has camp mediated vasodilated activity in the mesenteric vascular bed of the cat. Peptides, 1996, 17:1379-1387.
  • 7Sakata J, Shimokubo T, Kitamura K, et at. Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide, Biochem Biophys Res Commun, 1993,195:921-927.
  • 8Iwasaki H, Hirata Y, Iwashina M, et al. Specific binding site for proadrenomedullin N-terminal 20 peptide (PAMP) in the rat. Endocrinology, 1996, 137:3045-3050.
  • 9Belloni AS, Albertin G, Fomeris ML, et at. Proadrenomedullinderived peptides as autocrine-paracrine regulators of cell growth. Histol-Histopathol, 2001 , 16 : 1263-1274.

二级参考文献2

共引文献14

同被引文献48

  • 1徐萍,刘进,张钧.肾上腺髓质素与高血压[J].心血管康复医学杂志,2005,14(1):87-89. 被引量:2
  • 2Etoh T, Kato J, Takenaga M, et al. Differential hormonal profiles of adrenomedullin and proadrenomedullin N- terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels [J]. Clin Cardiol, 1999, 22 (2): 113-- 119.
  • 3Tsuruda T, Kato J, Hatakeyama K, et al. Antifibrotie effect of adrenomedullin on coronary adventltia in angiotensin Ⅱ-- induced hypertensive rats [J]. Cardiovasc Res, 2005, 65 (4):921--929.
  • 4Shimosawa T, Ando K, Fujita T, et al. A newly indentified peptide, proadrenomedullin N-- terminal 20 peptide induces hypotensive action via pertussis toxin sensitive mechanisms [J]. Hypertension, 1997, 30: 1009--1014.
  • 5Ishiyama T, Kitamura K, Ichiki Y, et al. Haemodynamia effects of a novel hypotensive peptide, human adrenomedullin in rats [J]. Eue J Pharmacol, 1993, 241: 271.
  • 6Tsuruda T, Kato J, Eto T. Effect of adrenomedullin on cardiac myocytes and fibroblasts [J]. Nippon Rinsho, 2004, 62 (Suppl 9): 233--236.
  • 7Qi YF, Bu DF, Niu DD, et al. Effects of different peptide fragments derived from proadrenomedullin on gene expression of adrenomedullin gene [J]. Peptides, 2002, 23 (6): 1141--1147.
  • 8Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N--terminal 20 peptide (PAMP), hypotensive and vasoditating peptides[J]. Peptides, 2001, 22 (11): 693--711.
  • 9Kitamura K. PAMP: novel hypotensive peptide derived from adrenomedullin precursor [J]. Nippon Rinsho, 2004, 62 (Suppl 9) : 203--206.
  • 10Nagatomo T, Shibuy AI, Kabashma N, et al. Proadrenomedullin N -- terminal 20 peptide (PAMP) reduces inward currents and Ca^2+ rises induced by nicotine bovine adrenal medullarycells [J]. Life Sci, 1996, 59 (20): 1723--1730.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部